# Michele Gaiotto

> Michele Gaiotto is a seed investor at HTH backing Biotechnology. See 2 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [HTH](https://shizune.co/investors/profile/hth)
- Location: Milan, Italy
- Total investments: 2
- Last investment: Jun 2024
- Lead investor: 50%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/michele-gaiotto-26386939
- X (Twitter): https://twitter.com/kiliz88

Michele Gaiotto is a seed investor at HTH in Milan focused on Biotechnology and Health Care. Michele Gaiotto is the Founder and Managing Principal of HTH. He Previously worked at SOM Biotech as a Member of the Board of Directors. Michele Gaiotto attended the University of Padova.

## Contacts

5 contacts available for Michele Gaiotto: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/michele-gaiotto?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Medical Device | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 50% |
| United Kingdom | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EpilepsyGTx | EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy (FRE). | $10M | Seed | Jun 24, 2024 | https://www.epilepsygtx.com/ |
| Leuko | Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel,blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes. | $5M | Series A | Sep 23, 2022 | https://leuko.com |

2 of 2 investments shown.

## Co-investors
- [Good Growth Capital](https://shizune.co/investors/profile/good-growth-capital) — VC Fund, 1 deal together
- [IAG Capital Partners](https://shizune.co/investors/profile/iag-capital-partners) — VC Fund, 1 deal together
- [MassVentures](https://shizune.co/investors/profile/massventures) — VC Fund, 1 deal together
- [Nina Capital](https://shizune.co/investors/profile/nina-capital) — VC Fund, 1 deal together
- [UCL Technology Fund](https://shizune.co/investors/profile/ucl-technology-fund) — VC Fund, 1 deal together

## About HTH

VC Fund · Milano, Italy

HTH is a private Life Science Investment Company. Headquartered in Milan (IT), the company invests worldwide in Biotech, Medtech, Digital Health with a special focus on AI enabled technologies (but not limited to).

1 contacts available at HTH.

| Name | Title | Profile |
| --- | --- | --- |
| Michele Gaiotto | Managing Principal and Founder | https://shizune.co/investors/profile/michele-gaiotto |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

## FAQ

### What does Michele Gaiotto invest in?

Michele Gaiotto invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Michele Gaiotto?

Public channels for Michele Gaiotto include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Michele Gaiotto last invest?

The most recent investment recorded for Michele Gaiotto closed in Jun 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co